- Company hosting a virtual analyst and investor event on September 3, 2024, at 8:00 am EDT to discuss results PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (ARWR) today ...
− Sustained Benefit of Vutrisiran Across Mortality, Cardiovascular Events, Quality of Life and Cardiac Biomarkers Observed Through Up to 48 Months, Including 12 Months from the Ongoing Open-Label ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results